72.65 USD
+0.18 (+0.25%)
72.65 USD
0 (0%)
RNA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. While RNA has a great health rating, there are worries on its profitability. RNA is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- In the past year RNA has reported negative net income.
- In the past year RNA has reported a negative cash flow from operations.
- In the past 5 years RNA always reported negative net income.
- RNA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a decent Return On Assets value of -25.76%, RNA is doing good in the industry, outperforming 71.05% of the companies in the same industry.
- With a decent Return On Equity value of -29.15%, RNA is doing good in the industry, outperforming 76.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.76% | ||
| ROE | -29.15% | ||
| ROIC | N/A |
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for RNA has been increased compared to 1 year ago.
- The number of shares outstanding for RNA has been increased compared to 5 years ago.
- There is no outstanding debt for RNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 25.62 indicates that RNA is not in any danger for bankruptcy at the moment.
- RNA has a Altman-Z score of 25.62. This is amongst the best in the industry. RNA outperforms 91.62% of its industry peers.
- RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 25.62 |
ROIC/WACCN/A
WACC8.94%
2.3 Liquidity
- A Current Ratio of 11.57 indicates that RNA has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 11.57, RNA belongs to the top of the industry, outperforming 86.10% of the companies in the same industry.
- A Quick Ratio of 11.57 indicates that RNA has no problem at all paying its short term obligations.
- The Quick ratio of RNA (11.57) is better than 86.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.57 | ||
| Quick Ratio | 11.57 |
3. Growth
3.1 Past
- The earnings per share for RNA have decreased strongly by -45.14% in the last year.
- RNA shows a strong growth in Revenue. In the last year, the Revenue has grown by 106.27%.
- RNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.26% yearly.
EPS 1Y (TTM)-45.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-95.38%
Revenue 1Y (TTM)106.27%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%434.03%
3.2 Future
- RNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.26% yearly.
- Based on estimates for the next years, RNA will show a very strong growth in Revenue. The Revenue will grow by 180.61% on average per year.
EPS Next Y-57.21%
EPS Next 2Y-33.66%
EPS Next 3Y-14.9%
EPS Next 5Y23.26%
Revenue Next Year134.19%
Revenue Next 2Y66.31%
Revenue Next 3Y223.72%
Revenue Next 5Y180.61%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for RNA. In the last year negative earnings were reported.
- Also next year RNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RNA's earnings are expected to decrease with -14.90% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.66%
EPS Next 3Y-14.9%
5. Dividend
5.1 Amount
- RNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
72.65
+0.18 (+0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners102.67%
Inst Owner Change-0.2%
Ins Owners0.83%
Ins Owner Change1%
Market Cap10.95B
Revenue(TTM)20.87M
Net Income(TTM)-549.79M
Analysts67.78
Price Target74.07 (1.95%)
Short Float %6.18%
Short Ratio3.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.79%
Min EPS beat(2)-21.39%
Max EPS beat(2)-14.2%
EPS beat(4)1
Avg EPS beat(4)-8.77%
Min EPS beat(4)-21.39%
Max EPS beat(4)0.55%
EPS beat(8)3
Avg EPS beat(8)-3.28%
EPS beat(12)7
Avg EPS beat(12)1.34%
EPS beat(16)9
Avg EPS beat(16)0.21%
Revenue beat(2)2
Avg Revenue beat(2)324.5%
Min Revenue beat(2)158.88%
Max Revenue beat(2)490.11%
Revenue beat(4)3
Avg Revenue beat(4)181.01%
Min Revenue beat(4)-18.03%
Max Revenue beat(4)490.11%
Revenue beat(8)4
Avg Revenue beat(8)76.22%
Revenue beat(12)8
Avg Revenue beat(12)57.88%
Revenue beat(16)10
Avg Revenue beat(16)42.54%
PT rev (1m)0%
PT rev (3m)6.61%
EPS NQ rev (1m)2.28%
EPS NQ rev (3m)-1.39%
EPS NY rev (1m)1.37%
EPS NY rev (3m)-1.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)71.39%
Revenue NY rev (1m)14.63%
Revenue NY rev (3m)110.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 524.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.8 | ||
| P/tB | 5.8 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.18
EYN/A
EPS(NY)-5.16
Fwd EYN/A
FCF(TTM)-3.95
FCFYN/A
OCF(TTM)-3.85
OCFYN/A
SpS0.14
BVpS12.52
TBVpS12.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.76% | ||
| ROE | -29.15% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 439.11% | ||
| Cap/Sales | 71.4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.57 | ||
| Quick Ratio | 11.57 | ||
| Altman-Z | 25.62 |
F-Score3
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)219.55%
Cap/Depr(5y)307.52%
Cap/Sales(3y)46.55%
Cap/Sales(5y)39.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-95.38%
EPS Next Y-57.21%
EPS Next 2Y-33.66%
EPS Next 3Y-14.9%
EPS Next 5Y23.26%
Revenue 1Y (TTM)106.27%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%434.03%
Revenue Next Year134.19%
Revenue Next 2Y66.31%
Revenue Next 3Y223.72%
Revenue Next 5Y180.61%
EBIT growth 1Y-88.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-86.27%
EBIT Next 3Y-17.56%
EBIT Next 5YN/A
FCF growth 1Y-232.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-232.19%
OCF growth 3YN/A
OCF growth 5YN/A
AVIDITY BIOSCIENCES INC / RNA FAQ
Can you provide the ChartMill fundamental rating for AVIDITY BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 4 / 10 to RNA.
What is the valuation status of AVIDITY BIOSCIENCES INC (RNA) stock?
ChartMill assigns a valuation rating of 0 / 10 to AVIDITY BIOSCIENCES INC (RNA). This can be considered as Overvalued.
Can you provide the profitability details for AVIDITY BIOSCIENCES INC?
AVIDITY BIOSCIENCES INC (RNA) has a profitability rating of 1 / 10.
What is the financial health of AVIDITY BIOSCIENCES INC (RNA) stock?
The financial health rating of AVIDITY BIOSCIENCES INC (RNA) is 8 / 10.
Can you provide the expected EPS growth for RNA stock?
The Earnings per Share (EPS) of AVIDITY BIOSCIENCES INC (RNA) is expected to decline by -57.21% in the next year.